Work

A319 Clonal hematopoiesis of indeterminate potential: a novel thromboinflammatory risk modifier in neurointervention

Year: 2026
Type: conference-abstract
Abstract: Background/Introduction Clonal hematopoiesis of indeterminate potential (CHIP) somatic mutations in hematopoietic stem cells at a variant allele frequency (VAF) ≥2% without hematologic malignancy, affects 10–15% of adults over age 65. Although CHIP doubles atherosclerotic cardiovascular risk via pro-inflammatory pathways, its specific role in cerebrovascular disease and neurointerventional decision-making remains under-explored. Objective/Purpose To evaluate CHIP as an actionable, gene-specific cerebrovascular risk modifier and propose novel applications for neurointerventional practice. Methods/Case Description A structured synthesis of prospective cohorts, biobank datasets (>800,000 participants), Mendelian randomization studies, and mechanistic data published through 2026 was performed, evaluating stroke subtype specificity, thromboinflammatory mechanisms, and secondary prevention strategies. Results/Findings CHIP is an independent determinant of incident stroke (HR 1.20, p=1.92×10−10). Risk is driver-dependent: JAK2 confers the highest risk (HR 2.52), followed by TET2 (HR 1.23) and DNMT3A (HR 1.13). In established ischemic stroke, CHIP positivity predicts elevated composite secondary events (HR 1.55), with VAF ≥10% conferring independent prognostic weight. Mechanistically, TET2 and DNMT3A induce NLRP3/AIM2 inflammasome hyperactivation within atherosclerotic plaques, whereas JAK2 drivers stimulate neutrophil extracellular trap formation and platelet hyperactivation. Interleukin-1 (IL-1) pathway signaling modulates this risk, identifying a targetable inflammatory axis. Discussion/Conclusions/Learning Points CHIP represents a biologically plausible, measurable target for precision neurointervention. We propose three clinical paradigms: refining carotid revascularization thresholds in high-risk mutation carriers (TET2, JAK2, VAF ≥10%); tailoring secondary prevention using targeted antiplatelet agents or anti-inflammatory therapies (IL-1 pathway inhibitors, colchicine) post-revascularization; and intensifying post-procedural imaging surveillance in large-clone CHIP. Integrating targeted peripheral blood next-generation sequencing into clinical workflows enables prospective validation of mutation-specific neurointerventional algorithms.
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W7204998597
Cites:
Cited by:
Related to: 9